STCube

STCube Net Debt

The Net Debt of STCube (052020.KQ) as of Oct 24, 2026 is -79.55 B KRW. In the previous year, Net Debt was -33.00 B KRW — a change of 141.07% (lower).

Net Debt

-79.55 BKRW

YoY

141.07%

Last updated:

Net Debt of STCube is 2024 -79.55 B KRW. Net Debt of STCube was 2023 -33.00 B KRW. It decreases by 141.07% lower compared to the previous year.

The STCube Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2017
-7.35 B KRW
Jan 1, 2018
-31.39 B KRW
Jan 1, 2019
-28.72 B KRW
Jan 1, 2020
5.21 B KRW
Jan 1, 2021
-15.32 B KRW
Jan 1, 2022
-49.94 B KRW
Jan 1, 2023
-33.00 B KRW
Jan 1, 2024
-79.55 B KRW
The STCube Net Debt history
YEARNet DebtYoY
-79.55 BKRW+141.07%
-33.00 BKRW-33.92%
-49.94 BKRW+226.00%
-15.32 BKRW-394.11%
5.21 BKRW-118.14%
-28.72 BKRW-8.52%
-31.39 BKRW+327.27%
-7.35 BKRW-56.57%
-16.92 BKRW+144.90%
-6.91 BKRW-197.45%
7.09 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

STCube Stock analysis

What does STCube do? STCube Inc. generates revenue through its two business segments. The IT segment distributes CCTV lenses and related components, targeting businesses requiring security solutions. The BT segment develops and licenses immunomodulatory anticancer drug therapeutic candidates, selling to pharmaceutical companies and research institutions. Both segments operate under the company's brand, leveraging its IT and biotechnology expertise. The IT segment focuses on closed-circuit television lens distribution, serving commercial and industrial clients seeking reliable security infrastructure. The BT segment's drug development and licensing activities cater to the pharmaceutical industry, providing innovative therapeutic candidates for cancer treatment. These offerings align with STCube's dual expertise in technology and biotechnology. STCube's revenue streams are derived from product distribution in the IT sector and licensing agreements in the biotechnology sector. The company's clients include businesses needing CCTV components and pharmaceutical firms interested in anticancer drug development. This dual approach allows STCube to serve distinct market segments with specialized solutions. STCube is one of the most popular companies on Eulerpool.

Frequently Asked Questions about STCube stock

Net Debt of STCube is -79.55 B KRW in 2024.

Net Debt of STCube changed from -33.00 B KRW to -79.55 B KRW, representing a 141.07% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Debt STCube since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's STCube historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — STCube

All Key Metrics — STCube